NF-kappaB in human disease: current inhibitors and prospects for de novo structure based design of inhibitors.
about
Plant and animal pathogen recognition receptors signal through non-RD kinasesSignaling pathways of bisphenol A-induced apoptosis in hippocampal neuronal cells: role of calcium-induced reactive oxygen species, mitogen-activated protein kinases, and nuclear factor-kappa BNuclear translocation of p65 NF-kappaB is sufficient for VCAM-1, but not ICAM-1, expression in TNF-stimulated smooth muscle cells: Differential requirement for PARP-1 expression and interactionAdvances in carcinogenic metal toxicity and potential molecular markersMechanistic role of a disease-associated genetic variant within the ADAM33 asthma susceptibility gene.Role of the ubiquitin system and tumor viruses in AIDS-related cancer.A selective small-molecule nuclear factor-kappaB inhibitor from a high-throughput cell-based assay for "activator protein-1 hits".The antiapoptotic activity of melatonin in neurodegenerative diseases.Anti-Inflammatory and PPAR Transactivational Effects of Oleanane-Type Triterpenoid Saponins from the Roots of Pulsatilla koreanaInhibition of choriodecidual cytokine production and inflammatory gene expression by selective I-kappaB kinase (IKK) inhibitors.Inhibiting NF-κB activation by small molecules as a therapeutic strategy.Functional characterization of a competitive peptide antagonist of p65 in human macrophage-like cells suggests therapeutic potential for chronic inflammation.Lytic HSV-1 infection induces the multifunctional transcription factor Early Growth Response-1 (EGR-1) in rabbit corneal cellsAnti-Inflammatory Potential of Ethanolic Leaf Extract of Eupatorium adenophorum Spreng. Through Alteration in Production of TNF-α, ROS and Expression of Certain GenesProgrammable oligomers targeting 5'-GGGG-3' in the minor groove of DNA and NF-kappaB binding inhibition.Novel p65 binding glucocorticoid-induced leucine zipper peptide suppresses experimental autoimmune encephalomyelitisProtective effect of α-lipoic acid against radiation-induced fibrosis in mice.Caffeic Acid Phenylethyl Ester and MG-132 Have Apoptotic and Antiproliferative Effects on Leukemic Cells But Not on Normal Mononuclear Cells.A genetically encoded bioluminescent indicator for illuminating proinflammatory cytokinesNO-donating aspirin inhibits the activation of NF-kappaB in human cancer cell lines and Min mice.Prohibitin as an oxidative stress biomarker in the eyeDirect Rel/NF-κB inhibitors: structural basis for mechanism of action.Natural and synthetic α,β-unsaturated carbonyls for NF-κB inhibition.A new assay format for NF-kappaB based on a DNA triple helix and a fluorescence resonance energy transfer.Neurotoxic effects of bisphenol AF on calcium-induced ROS and MAPKs.Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistanceImmediate early gene-X1 interferes with 26 S proteasome activity by attenuating expression of the 19 S proteasomal components S5a/Rpn10 and S1/Rpn2.Protective Effects of Nobiletin Against Endotoxic Shock in Mice Through Inhibiting TNF-α, IL-6, and HMGB1 and Regulating NF-κB Pathway.Influence of dexamethasone on inflammatory mediators and NF-kappaB expression in multiple organs of rats with severe acute pancreatitisTheoretical studies on pyrimidine substituent derivatives as dual inhibitors of AP-1 and NF-kappaB.Hepatitis C virus F protein inhibits cell apoptosis by activation of intracellular NF-kappaB pathway.Patented inhibitors (2002 - 2005) of the transcription factor NF-kappaB.MMP-2 silencing reduces the osteogenic transformation of fibroblasts by inhibiting the activation of the BMP/Smad pathway in ankylosing spondylitis.Effects of insulin-like growth factor-1 on rotenone-induced apoptosis in human lymphocyte cells.Inhibitory effects of oleanane-type triterpenes and saponins from the stem bark of Kalopanax pictus on LPS-stimulated pro-inflammatory cytokine production in bone marrow-derived dendritic cellsElevated metabolic rate and skeletal muscle oxidative metabolism contribute to the reduced susceptibility of NF-κB p50 null mice to obesity
P2860
Q21131622-F74A3A20-8753-4E72-8F4E-264D6C6B2064Q23921520-C5DEB2A6-E014-4C10-83CE-BE856424D8B3Q24647748-CFE7BF78-3BA9-4608-832D-55BB065EA1BAQ27015019-88295EFA-AE8A-4079-B9D1-3B0502C7180FQ33291238-0DD9975A-60DD-484F-A73E-5B913D8530EEQ33307881-6D8BF537-1B36-47E4-B0E2-F55E7E5053AEQ33414478-CE0D72DE-530E-4ECD-98B4-816BAB5F77D6Q33757816-306C17B7-6C28-4B3D-995C-3157CB0BAF0BQ34039797-D8C3F173-381B-4716-BB01-30AD94033181Q34116837-85B99B01-4774-4359-ABE0-C3F1434BF5CEQ34205025-D3D1A47E-D89C-4CB4-A34A-2D3D8F3B7D77Q34672342-BDC31167-D52E-4D21-9238-E454E9BBAC73Q35061490-A16B8105-97CD-491F-A95F-DB6DE27D487BQ35132981-ABD870A1-778E-44A5-BC79-87AEEA260253Q35526008-83F04BC4-FA40-4D15-BEBE-4CFA02FB9C1FQ35639706-232031C9-BCB6-4E87-84EB-C05576CD589EQ37085820-38028278-4968-4A67-87C4-6670C7D960BFQ37109468-1A40A46B-BF18-4161-9766-92DEE54DE23FQ37127885-D53D04D6-D81F-41BE-AD5B-95FA3DF6B718Q37185879-55966E9B-1EF6-4F65-874C-93D9384E98E6Q37501904-23C75907-EDA8-4C92-9289-7B10FE64E0AFQ37855820-AA181DD8-4525-4E87-837F-AA7F48694D99Q37855873-60C2E66D-4C0E-485A-83C9-4940D35F51C3Q38350440-59F5E3A3-1264-4402-A1D2-ED3BEE7F3A88Q39274727-E9F7F130-2BD8-4D03-9108-8942FC077F94Q39908141-79B5882E-9086-445B-B122-35CE7F3DA313Q40208275-BD02DE92-BE39-4250-879A-B60445F33A60Q40804605-0D34B9EE-40B6-431B-9686-8B4F5F5AE124Q40970581-65140EED-2C45-4E42-9E79-61509C43C993Q43234736-F0004806-1566-4F13-9FDE-2F87C2EAB9D6Q43701603-974283DF-1866-4E68-84B6-3B7DC475690AQ45856870-44F0B816-F9D6-4A2A-885E-9125291888C0Q49677530-4BD94FE1-F24B-45B1-B30D-89BFC38A7A90Q52699757-488D514A-C9CA-4F2E-92CD-7E9AF90785CEQ57224225-5755C3DE-CE85-403D-83B2-025F185656BAQ58699521-7CFD51BE-D346-424C-910C-9EC3B7DF2283
P2860
NF-kappaB in human disease: current inhibitors and prospects for de novo structure based design of inhibitors.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
NF-kappaB in human disease: cu ...... re based design of inhibitors.
@ast
NF-kappaB in human disease: cu ...... re based design of inhibitors.
@en
type
label
NF-kappaB in human disease: cu ...... re based design of inhibitors.
@ast
NF-kappaB in human disease: cu ...... re based design of inhibitors.
@en
prefLabel
NF-kappaB in human disease: cu ...... re based design of inhibitors.
@ast
NF-kappaB in human disease: cu ...... re based design of inhibitors.
@en
P356
P1476
NF-kappaB in human disease: cu ...... re based design of inhibitors.
@en
P2093
P304
P356
10.2174/0929867053363180
P577
2005-01-01T00:00:00Z